Earning are out. Obviously the actual earnings ar

Earning are out. Obviously the actual earnings are a little less important than guidance on a new direction in light of the poor Mydicar for heart failure phase II results. Apparently the company is still investigating the causes of the trial's failure to meet endpoints. The stock is down $0.08 to $2.27 in after hours.

"We are in the process of conducting an extensive review of the CUPID2 data in the attempt to better understand the observed negative outcome. Meanwhile, we are conserving our cash resources and are assessing our other previously planned clinical trials and development programs. We are also evaluating our strategic options in order to determine the best path forward to maximize shareholder value," said Krisztina Zsebo, Ph.D., Chief Executive Officer of Celladon.

Since it has been two and a half weeks since the press release regarding the phase II trials it would have been great if they had a little more information or guidance. Hopefully they'll put out a press release when they evaluate the data and determine a new direction.

Yes, I understand your penny stock also is the real deal, created with the inventiveness of Edison and destined to be the next Microsoft. Yes, I understand that the delays are also only because your company is making their product and/or technology even more revolutionary.